News Feed

NEW DELHI: The Indian pharmaceutical market has shown robust value growth of 9.2% with major therapies recording a double-digit increase in December.

Among the top therapies, cardiac, anti-infectives and neuro/central nervous system have shown a relatively stronger volume growth last month, according to data from research firm PharmaTrac. Antibiotic drug Augmentin and anti-diabetes Glycomet GP continued to be the top-selling medicine brands.

"For December, the market has definitely shown very good and encouraging value growth. All the three growth levers - new introductions, price and volume - are positive for the month," said Sheetal Sapale, vice president-commercial at PharmaTrack.

Augmentin recorded sales of Rs 76 crore in December, according to data from the company's research report. Between December 2022 and December 2023, the sales totalled Rs 804 crore.

For Glycomet GP, sales were Rs 67 crore (last month) and Rs 778 crore (from December 2022).

While Augmentin has shown a moving annual total (MAT) growth rate of 9.9%, Glycomet GP has recorded 6.6%.

Mankind's condom brand Manforce continued to retain its third position in December, showing a MAT growth rate of 12.5%. It posted sales of Rs 56 crore in December 2023.

The Indian pharma market has recorded unit growth of 2.2% in December, which remains to be small, Sapale said.